Abstract 546P
Background
Malignant pleural mesothelioma (MPM) is an asbestos-related fatal malignant neoplasm. Although combination therapy of ipilimumab plus nivolumab has proven to bring about a better outcome in patients with MPM, long-term survival remains unsatisfactory. To further improve the prognosis, developing a novel treatment strategy to maximize the antitumor effect of ICI is a pressing issue. We examined whether nintedanib, an antiangiogenic agent, could augment the antitumor effect of anti-PD-1 antibody (Ab).
Methods
We established subcutaneous mice mesothelioma allograft model. Mice were treated either with vehicle, anti-PD-1 Ab, nintedanib or anti-PD-1 Ab plus nintedanib. Tumor size was routinely measured with a caliper. Mice were euthanized before they became moribund, and allografts were collected for histological analyses. Angiogenesis and infiltrating immune cells were assessed by immunohistochemistry (IHC). We further performed ex vivo study using bone marrow-derived macrophages (BMDMs) to elucidate the antitumor mechanism of the combination therapy of anti-PD-1 Ab plus nintedanib.
Results
Nintedanib significantly suppressed the growth of mesothelioma allografts. Combination therapy with anti-PD-1 Ab plus nintedanib reduced tumor burden more dramatically compared with nintedanib monotherapy. IHC analyses revealed that nintedanib not only inhibited angiogenesis but also decreased the infiltration of tumor-associated macrophages (TAMs). Moreover, ex vivo study using BMDMs showed that nintedanib could polarize TAMs from M2 to M1 phenotype. Thus, nintedanib could suppress protumor activity of TAMs both numerically and functionally. On the other hand, nintedanib upregulated the expression of PD-1 and PD-L1 in BMDMs and mesothelioma cells, respectively, and impaired the phagocytic activity of BMDMs against mesothelioma cells. Co-administration of anti-PD-1 Ab may reactivate phagocytic activity of BMDMs by disrupting nintedanib-induced immunosuppressive signal.
Conclusions
Combination therapy of anti-PD-1 Ab plus nintedanib exerts synergistic antitumor activity and can become a novel therapeutic option for patients with MPM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Minami: Financial Interests, Institutional, Research Grant: Nippon Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract